The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders
Neurodegenerative disorders are responsible for malfunctioning of brain and peripheral nervous system. The therapeutic drugs that are commonly utilized for the treatment of these disorders are not able to pass through the blood–brain barrier (BBB) as it permits passage of specific nutrients which are helpful for growth. Thus, nanotechnology (NT) can be very much valuable in solving this problem as there are different forms of nanomaterials that can act as efficient drug delivery systems and help in crossing the BBB and providing effective treatment for neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and many more. Thus, in this chapter, we tried to conglomerate all the recent developments related to neurodegenerative disorders and also provide a brief overview about the importance of nanotechnology in varied biomedical applications.
KeywordsNeurodegenerative disease Nanoparticles Blood–brain barrier Nanotechnology
The author is thankful to GITAM University, Visakhapatnam, Andhra Pradesh, India, for providing financial support and facilities to carry out this review.
Conflicts of Interest
The author has declared that no conflicts of interest exist.
- Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053. https://doi.org/10.1200/JCO.2005.06.205CrossRefPubMedPubMedCentralGoogle Scholar
- Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102(7):2273–2276. https://doi.org/10.1073/pnas.0409336102CrossRefPubMedPubMedCentralGoogle Scholar
- Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102(51):18620–18625. https://doi.org/10.1073/pnas.0509591102CrossRefPubMedPubMedCentralGoogle Scholar
- Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as a knowledge representation for clinical questions. AMIA … annual symposium proceedings. AMIA Symposium 2006:359–363Google Scholar
- Prinster A (2006) Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. NeuroImage; 29:859–867. [PubMed: 16203159]Google Scholar
- Shyam S, Arshad F, Abdul Ghani R, Wahab NA, Safii NS, Nisak MY, Kamaruddin NA (2013) Low glycaemic index diets improve glucose tolerance and body weight in women with previous history of gestational diabetes: a six months randomized trial. Nutr J 12:68. https://doi.org/10.1186/1475-2891-12-68CrossRefPubMedPubMedCentralGoogle Scholar
- Schrag A, Quinn NP, Ben-Shlomo Y (2006) Heterogeneity of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006;77:275–276. [PubMed: 16421140]Google Scholar
- Saltzman WM (1999) Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm Res 16:232–240. [PubMed: 10100308]Google Scholar
- Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, De Martino M (2005) Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 3(35):143–153. https://doi.org/10.1016/j.semarthrit.2005.08.007CrossRefGoogle Scholar